COSM (Cosmos Health) ROE %: -58.67% (As of Mar. 2026)


COSM Cosmos Health Inc COSM
29 GF Score
Price $0.19
GF Value $0.36
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Cosmos Health ROE %?

Cosmos Health COSM -10.91% 29 ROE % is -58.67% as of Mar. 2026. GuruFocus rates COSM with a GF Score™ of 29/100 and a GF Value™ of $0.36 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 115 Medical Distribution companies, Cosmos Health ranks worse than 95.65% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Cosmos Health's annualized net income for the quarter that ended in Mar. 2026 was $-11.22 Mil. Cosmos Health's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was $19.13 Mil. Therefore, Cosmos Health's annualized ROE % for the quarter that ended in Mar. 2026 was -58.67%.

The historical rank and industry rank for Cosmos Health's ROE % or its related term are showing as below:

COSM' s ROE % Range Over the Past 10 Years
Min: -7304.59   Med: -62.81   Max: -48.99
Current: -93.04

During the past 13 years, Cosmos Health's highest ROE % was -48.99%. The lowest was -7,304.59%. And the median was -62.81%.

COSM's ROE % is ranked worse than
95.65% of 115 companies
in the Medical Distribution industry
Industry Median: 7.1 vs COSM: -93.04

Cosmos Health  (NAS:COSM) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-11.22/19.1255
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-11.22 / 71.712)*(71.712 / 63.9235)*(63.9235 / 19.1255)
=Net Margin %*Asset Turnover*Equity Multiplier
=-15.65 %*1.1218*3.3423
=ROA %*Equity Multiplier
=-17.56 %*3.3423
=-58.67 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-11.22/19.1255
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-11.22 / -11.22) * (-11.22 / -8.736) * (-8.736 / 71.712) * (71.712 / 63.9235) * (63.9235 / 19.1255)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.2843 * -12.18 % * 1.1218 * 3.3423
=-58.67 %

Note: The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Cosmos Health ROE % Related Terms


Cosmos Health ROE % Historical Data

* Premium members only.

The historical data trend for Cosmos Health's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cosmos Health ROE % Chart

Cosmos Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7,304.59 -62.81 -48.99 -53.43 -89.13

Cosmos Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.96 -43.35 -86.75 -195.30 -58.67

COSM vs HKPD, VNOV, SNYR: ROE % Comparison

For the Medical Distribution subindustry, Cosmos Health's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosmos Health ROE % vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Cosmos Health's ROE % distribution charts can be found below:

* The bar in red indicates where Cosmos Health's ROE % falls into.


COSM
29GF Score
Cosmos Health Inc COSM
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cosmos Health ROE % Calculation

Cosmos Health's annualized ROE % for the fiscal year that ended in Dec. 2025 is calculated as

ROE %=Net Income (A: Dec. 2025 )/( (Total Stockholders Equity (A: Dec. 2024 )+Total Stockholders Equity (A: Dec. 2025 ))/ count )
=-19.145/( (24.533+18.425)/ 2 )
=-19.145/21.479
=-89.13 %

Cosmos Health's annualized ROE % for the quarter that ended in Mar. 2026 is calculated as

ROE %=Net Income (Q: Mar. 2026 )/( (Total Stockholders Equity (Q: Dec. 2025 )+Total Stockholders Equity (Q: Mar. 2026 ))/ count )
=-11.22/( (18.425+19.826)/ 2 )
=-11.22/19.1255
=-58.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. ROE % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of -58.67% mean?
Cosmos Health (COSM) has a ROE % of -58.67% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Cosmos Health and its competitors. According to the industry distribution chart, Cosmos Health ranks #110 out of 115 companies in the Medical Distribution industry, placing it in the top 95.7%.
Is Cosmos Health's ROE % too high?
Cosmos Health's current ROE % is -58.67%. Based on the distribution chart, Cosmos Health ranks #110 out of 115 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Cosmos Health has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cosmos Health's ROE % compare to HKPD and VNOV?
According to the Medical Distribution industry distribution chart, Cosmos Health ranks #110 out of 115 companies for ROE %. This places Cosmos Health in the lower half of its industry. The industry median ROE % is 7.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Distribution company?
The median ROE % among Medical Distribution companies is 7.10, based on 115 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Cosmos Health and its competitors. For the Medical Distribution industry, the median ROE % is 7.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmos Health's current ROE % is -58.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmos Health stock overvalued right now?
Based on GuruFocus' analysis, Cosmos Health (COSM) is currently considered Possible Value Trap. The stock's GF Value™ is $0.36, compared to a current price of $0.19 — trading 48.5% below its estimated fair value. The current ROE % is -58.67%. Cosmos Health's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Cosmos Health (COSM), the current ROE % is -58.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cosmos Health (COSM) Overvalued in 2026?

Based on GuruFocus' analysis, Cosmos Health stock appears to be undervalued. The current stock price of $0.19 is trading 48.5% below its estimated GF Value™ of $0.36. GuruFocus considers Cosmos Health to be Possible Value Trap.

Key valuation signals for COSM:

  • ROE %: -58.67%
  • GF Value™: $0.36 vs. price of $0.19 (48.5% below fair value)
  • GF Score™: 29/100 with 6 warning signs

No single metric tells the full story. See the COSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cosmos Health Business Description

Other Exchanges V67A:Germany
Address 5 Agiou Georgiou Street, Pilea, Thessaloniki, GRC, 55438
Cosmos Health Inc is a diversified, vertically integrated healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of medicines and repurposing drugs as well as operator of a telehealth platform. The company has developed its own proprietary branded nutraceutical products, named 'Sky Premium Life' and 'Mediterranation'. Its product portfolio includes generics and over-the-counter pharmaceutical products, medicines, as well as nutraceuticals and biocides. The company's Reportable segments are Wholesale, Pharma manufacturing, and Nutraceutical and pharmaceuticals, with the majority of revenue generated from the Wholesale segment.
29GF Score

Get the complete analysis for COSM

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.19
Price
$0.36
GF Value